Ozempic Coverage Cut Sparks Controversy Among American Airlines Flight Attendants

American Airlines (AA), which almost a week ago announced the expansion of its summer routes, has announced that, effective 1 January 2026, its employee health plan will restrict coverage of GLP-1 (glucagon-like peptide-1) medications for weight management. Only crew members with a diagnosis of Type 2 diabetes will retain coverage for drugs such as Ozempic and Mounjaro; those using  Wegovy and Saxenda will be completely excluded.

The decision has provoked a strong reaction from the Association of Professional Flight Attendants (APFA), the union representing the carrier’s flight crews, says that this change “reduces the value of your healthcare coverage and strips treatment options Members rely on for prevention and quality of life“.

Which are the ten most punctual US airlines for January 2025?

Category	Details
Full Name	American Airlines, Inc.
Parent Company	American Airlines Group
Headquarters	Fort Worth, Texas, U.S.
Airline Codes	IATA: AA, ICAO: AAL
CEO	Robert Isom
Alliance	Oneworld (founding member)
Destinations & Network	Over 350 destinations in more than 60 countries.
Fleet Size (mainline)	Approximately 1000 aircraft (2025)
Key Fleet Types	Airbus A319, A320, A321/neo; Boeing 737-800, 787-8/9, 777-200/300
Fleet Modernisation	Since 2013, 600+ new aircraft delivered; youngest fleet among U.S. network carriers.

American Airlines Flight Attendant’s Policy Change Details

American Airlines’ announcement which can be seen in Association of Professional Flight Attendants(APFA) says that the health-plan will:

” only cover GLP-1 medications for individuals with type 2 diabetes. Within that group, coverage will be limited only to Ozempic® and Mounjaro®. This means that Wegovy® and Saxenda® will be completely excluded from coverage, even if medically necessary or prescribed by your physician.”

Medication	Some Benefits *
Ozempic® (semaglutide)	Approved for type 2 diabetes management; significantly lowers blood sugar levels and HbA1c. Promotes weight loss as a secondary benefit by reducing appetite and slowing gastric emptying. May support kidney and heart health in people with diabetes. Sources: UC Davis, Heathline
Mounjaro® (tirzepatide)	Dual-acting GIP + GLP-1 receptor agonist approved for type 2 diabetes improves glucose control more effectively than some older diabetes drugs Demonstrates substantial weight-loss results in clinical trials. Potential benefits include improved insulin sensitivity and cardiovascular markers. Sources: Diabetes UK, UC Health, FDA Label (Eli Lilly)
Wegovy® (semaglutide)	Approved specifically for chronic weight management in adults with obesity or overweight with related conditions. Produces clinically significant weight loss and may improve blood sugar and heart-related outcomes. Shares many of Ozempic’s metabolic benefits but at a higher dose for weight control. Sources: Medical News Today
Saxenda® (liraglutide)	A GLP-1 receptor agonist approved for weight management Helps reduce appetite and calorie intake. Also shown to help maintain lost weight when combined with diet and exercise. Provides additional cardiovascular risk-reduction benefits in people with type 2 diabetes. Sources: Cleveland Clinic, NIH (PMC)

*Please note that these drugs might have their own side effects as well. Please learn about these in detail

After having a notification of the changes, the APFA said that “this change raises serious concerns for our Members”. It also highlighted that there were other alternatives such as:

• Introduction of copay limits to reduce members’ personal financial burden.
• Establishment of prior-authorization procedures to confirm medical necessity before treatment approval.
• Deployment of step-therapy frameworks that prioritize lower-cost, clinically effective alternatives before advancing to higher-priced medications.

What do the critics have to say?

President Donald Trump has said that he intends to bring down the costs of “Ozempic”, something he referred to “the fat loss drug”      to $150 from $1,300. According to Reuters, “Ozempic has a list price of about $1,000 for a month’s supply but is sold directly by Novo to cash-pay customers for $499 per month“. One Mile At a Time noted that the financial woes of American Airline might have led to the carrier cutting down its health benefits, whilst also praising the qualities of Ozempic:

drugs like Ozempic being used for weight loss. It does seem to be a “miracle” drug for weight loss, though I guess it remains to be seen if there are any long term health side effects….One thing is for sure — Ozempic has made a huge difference in many peoples’ lives, though the retail cost is outrageously expensive, at around $1,000 per month. For most people that’s unaffordable, and for that matter, it sure seems like a medication shouldn’t cost five figures per year….

adding that:

I also can’t say that I’m surprised to see American trying to cut costs with healthcare coverage. The company has very high labor costs, and is sort of struggling financially, as it’s significantly less profitable than Delta and United. The company has to find cost savings somewhere, and I guess this is the latest place it’s trying to do so.

Top 5: Ways in which US airports are adapting to cater to travelers with accessibility requirements

Bottom line

American Airlines’ decision to curb GLP-1 medication coverage for non-diabetic weight management among its crew signifies a striking intersection of the following dynamics:

• Employee health benefits
• Cost-control imperatives
• Union-employer dynamics

It is unsurprising that the exclusion of weight-loss uses of drugs such as Wegovy and Saxenda has brought forth strong union backlash, raising questions about the future of health-benefit design in this busiest airlines of the US.